HighTower Advisors
BBIO icon

HighTower Advisors’s BridgeBio Pharma BBIO Stock Holding History

HighTower Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41M Sell
45,831
-1,793
-4% -$126K ﹤0.01% 1452
2026
Q1 		$3.54M Sell
47,624
-44,362
-48% -$3.22M ﹤0.01% 1384
2025
Q4 		$7.04M Sell
91,986
-138,407
-60% -$9.09M 0.01% 1015
2025
Q3 		$12M Buy
230,393
+2,007
+0.9% +$97.9K 0.01% 779
2025
Q2 		$9.86M Buy
228,386
+251
+0.1% +$9.13K 0.01% 800
2025
Q1 		$7.89M Sell
228,135
-197
-0.1% -$6.64K 0.01% 862
2024
Q4 		$6.27M Buy
228,332
+5,001
+2% +$129K 0.01% 953
2024
Q3 		$5.69M Buy
223,331
+22,077
+11% +$580K 0.01% 981
2024
Q2 		$5.1M Buy
201,254
+1,992
+1% +$54.5K 0.01% 996
2024
Q1 		$6.16M Sell
199,262
-1,019
-0.5% -$34.7K 0.01% 879
2023
Q4 		$8.09M Buy
200,281
+1,045
+0.5% +$31.4K 0.01% 765
2023
Q3 		$5.25M Sell
199,236
-24,377
-11% -$692K 0.01% 911
2023
Q2 		$3.84M Buy
223,613
+15,000
+7% +$226K 0.01% 1016
2023
Q1 		$3.46M Buy
208,613
+228
+0.1% +$2.66K 0.01% 1021
2022
Q4 		$1.59M Hold
208,385
– – ﹤0.01% 1409
2022
Q3 		$2.07M Hold
208,385
– – 0.01% 1212
2022
Q2 		$1.89M Buy
208,385
+115
+0.1% +$962 ﹤0.01% 1290
2022
Q1 		$2.12M Sell
208,270
-10,652
-5% -$109K ﹤0.01% 1347
2021
Q4 		$3.65M Buy
218,922
+7,284
+3% +$308K 0.01% 1058
2021
Q3 		$9.92M Sell
211,638
-10,130
-5% -$543K 0.03% 533
2021
Q2 		$13.5M Buy
221,768
+3
+0% +$171 0.04% 413
2021
Q1 		$13.7M Buy
221,765
+1,357
+0.6% +$88.8K 0.04% 390
2020
Q4 		$15.7M Buy
220,408
+100
+0% +$4.82K 0.07% 278
2020
Q3 		$8.27M Hold
220,308
– – 0.04% 388
2020
Q2 		$7.18M Hold
220,308
– – 0.04% 410
2020
Q1 		$6.39M Buy
+220,308
New +$6.83M 0.04% 386

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HighTower Advisors's BBIO Position: Q2 2026 in Review

HighTower Advisors reduced its BridgeBio Pharma (BBIO) stake by 3.8% in Q2 2026, selling an estimated $126K and leaving 45,831 shares worth $3.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

HighTower Advisors first reported a position in BBIO in Q1 2020 and has held it in 26 quarters since. The position peaked at $15.7M in Q4 2020. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • HighTower Advisors held 45,831 shares of BridgeBio Pharma worth $3.41M as of Q2 2026.
  • HighTower Advisors sold 1,793 BridgeBio Pharma shares in Q2 2026, an estimated $126K.
  • BridgeBio Pharma made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1452 holding.
  • HighTower Advisors first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 26 quarters since.
  • HighTower Advisors's BridgeBio Pharma position peaked at $15.7M in Q4 2020.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.